|

SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study

RECRUITINGSponsored by Kiyuk Chang
Actively Recruiting
SponsorKiyuk Chang
Started2020-08-01
Est. completion2025-12-31
Eligibility
Age19 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05770687

Summary

Prospective trials performed on type 2 diabetes patients without established cardiovascular disease has shown that SGLT2 inhibitors reduce cardiovascular risk. No studies have yet examined the occurrence of cardiovascular disease in patients with acute myocardial infarction. The investigators designed the current study to evaluate the most ideal oral hypoglycemic agent in type 2 diabetes patients undergoing percutaneous coronary intervention for acute myocardial infarction. The investigators hypothesize that the use of SGLT-2 inhibitors will reduce cardiovascular events and modify left ventricular remodeling after myocardial infarctions.

Eligibility

Age: 19 Years+Healthy volunteers accepted
Inclusion Criteria:

* Acute myocardial infarction who were treated with percutaneous coronary intervention
* Type 2 diabetes mellitus
* Started SGLT2 inhibitors \<1 month before/after PCI

Exclusion Criteria:

* Type 1 diabetes mellitus
* Insulin / GLP-1 analogue users
* Previous users of SGLT2 inhibitors
* Pregnancy

Conditions4

DiabetesDiabetes Mellitus, Type 2Heart DiseaseMyocardial Infarction

Browse More Trials

Heart Disease trialsDiabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.